NGM Biopharmaceuticals, Inc.is a clinical-stage biopharmaceutical company developing novel therapeutics for the cardio-metabolic, liver, oncologic and ophthalmic diseases. The CompanyÔÇÖs product candidates include NGM282, NGM313, NGM386, NGM395, NGM120, NGM217 and NGM621. NGM282 is an engineered variant of the human hormone known as FGF19, which the Company is developing for the treatment of non-alcoholic steatohepatitis (NASH). NGM313 is an agonistic antibody selectively activating fibroblast growth factor receptor 1c-beta-klotho and has the potential as an insulin sensitizer for the treatment of type two diabetes and NASH. NGM386 and NGM395 are engineered variants of the human hormone known as GDF15, which is developed for the treatment of obesity. NGM120 is an antagonistic antibody binding glial cell-derived neurotrophic factor receptor alpha-like, or GFRAL, that is designed to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome, and cancer.
Number of employees : 210 people.
|Novel Therapeutics||103.54||100%||87.37||100%|| -15.62%|
|USD in Million
|United States||103.54||100%||87.37||100%|| -15.62%|
|USD in Million
|Vote ||Quantity||Free-Float||Company-owned shares||Total Float
|The Column Group LLC ||17,993,932||
|Merck & Co., Inc. ||12,955,016||
|Prospect Venture Partners ||4,925,000||
|Topspin Management LLC ||4,833,333||
|Rho Ventures ||3,766,666||
|William J. Rieflin ||2,772,535||
|Redmile Group LLC ||2,751,815||
|The Vanguard Group, Inc. ||2,184,809||
|Point72 Asset Management LP ||2,175,000||
|Tichenor Ventures LLC ||1,872,314||
|Company contact information|
NGM Biopharmaceuticals, Inc.
333 Oyster Point Boulevard
South San Francisco, CA 94080-7014
Phone : +1.650.243.5555
Web : http://www.ngmbio.com
Sector Bio Therapeutic Drugs
Connections : NGM Biopharmaceuticals, Inc.